Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096981 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL1920162 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL16160087 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28785913 | 0.78 | — | — | |
| SCHEMBL27256616 | 0.78 | — | — | |
| SCHEMBL275280 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL7100492 | 0.78 | CA1 (0.38) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL197339 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL27485803 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL5074743 | 0.76 | ALDH1A1 (0.40) | SMN1; SMN2CA14CA12ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103214355-B | A kind of method prepared containing methyl fluoride or aryl alkyl ketone | JIANGSU ZHONGDAN PHARMACEUTICAL RESEARCH Co.,Ltd. (CN) | 2016-02-17 | — | — | CN | disclosed |
| EP-1765764-B1 | PROCESS FOR THE PREPARATION OF 4,4-DIFLUORO-3-OXOBUTANOIC ACID ESTERS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| CN-103214355-A | Method for preparing fluorine-containing methyl or alkylaryl ketones | JIANGSU ZHONGDAN PHARMACEUTICAL RES CO LTD | 2013-07-24 | — | — | CN | disclosed |
| US-7355065-B2 | Process for the preparation of 4,4-difluoro-3-oxobutanoic acid esters | SYNGENTA CROP PROTECTION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20080004465-A1 | Process for the Preparation of 4,4-Difluoro-3-Oxobutanoic Acid Esters | SYNGENTA CROP PROTECTION, INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1765764-A1 | PROCESS FOR THE PREPARATION OF 4,4-DIFLUORO-3-OXOBUTANOIC ACID ESTERS | Syngeta Participations AG (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005612-A1 | PROCESS FOR THE PREPARATION OF 4,4-DIFLUORO-3-OXOBUTANOIC ACID ESTERS | SYNGENTA PARTICIPATIONS AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004465-A1 | Process for the Preparation of 4,4-Difluoro-3-Oxobutanoic Acid Esters | FFAR4, OGDH, AKR1C4 | SMN1; SMN2 2026/4885CA14 501/4885CA12 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.